Drug intelligence / Profile preview

Y4A CAR T cells

Development stage
Discontinued
Lead developer
Methodist Hospital Research Institute
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Y4A CAR T cells are a specific variant of mesothelin (MSLN)-targeted chimeric antigen receptor T cells that utilize a VHH (variable domain of heavy chain-only antibody) binding domain. This variant was derived from the parental JZQ-B4 VHH CAR through a single-amino acid alanine substitution at the fourth residue (Y4A) of the complementarity-determining region 3 (CDR3). Although the Y4A mutation was intended to tune affinity, the resulting CAR still maintains high affinity (below 100 nM) for both human and mouse MSLN. In preclinical studies, Y4A CAR T cells failed to discriminate between cells with high and low antigen expression, leading to severe on-target, off-tumor toxicity and failure to control tumor growth in mesothelioma models. Consequently, Y4A is primarily utilized as a high-affinity research tool or control in studies focused on affinity-tuning strategies for solid tumors.

Other names
Y4A MSLN CAR T cellsY-4A MSLN CAR T cellsY 4A MSLN CAR T cellsY4A VHH CAR T cellsY-4A VHH CAR T cellsY 4A VHH CAR T cells
02

Targets

Mesothelin

Beyond the preview

Go deeper on Y4A CAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y4A CAR T cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call